LAVA Therapeutics

Biotechnology
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.

$33.7M

Market Cap • 5/23/2025

2016

(9 years)

Founded

2021

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of NL

Utrecht

Headquarters • UT